At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 184 enrolled
Drug / intervention
BMS-986036 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults With Non-alcoholic Steatohepatitis
In Brief
A Phase 2 clinical trial evaluating BMS-986036 and Placebo for Non-Alcoholic Steatohepatitis. Completed, enrolled 184 participants across 17 sites.
Detailed Summary
The purpose of this study is to determine whether BMS-986036 is effective in the treatment of subjects with Non-alcoholic Steatohepatitis (NASH).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Alcoholic Steatohepatitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartMay 2015
Primary CompletionJan 2017
Study CompletionJun 2017
TodayJul 2026
First PostedApr 9, 2015
Enrollment StartMay 8, 2015
Primary CompletionJan 18, 2017
Study CompletionJun 19, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.2 years ago
Interventions
BMS-986036drug
BMS-986036drug
Placebodrug